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The functional contribution of myofibroblasts in fibrosis is not well understood [1] [2] [3] . Using a new genetic mouse model to track and isolate myofibroblasts, we performed gene expression profiling followed by biological validation to identify HE4 (encoding human epididymis protein 4, also known as WAP 4-disulfide core domain-2 or Wfdc2) as the most upregulated gene in fibrosis-associated myofibroblasts. The HE4 gene encodes for a putative serine protease inhibitor that is upregulated in human and mouse fibrotic kidneys and is elevated in the serum of patients with kidney fibrosis. HE4 suppresses the activity of multiple proteases, including serine proteases and matrix metalloproteinases, and specifically inhibits their capacity to degrade type I collagen. In particular, we identified two serine proteases, Prss35 and Prss23, as HE4 targets with functional relevance in kidney fibrosis. Administration of HE4-neutralizing antibodies accelerated collagen I degradation and inhibited fibrosis in three different mouse models of renal disease. Collectively these studies suggest that HE4 is a potential biomarker of renal fibrosis and a new therapeutic target.
Renal fibrosis is the scarring and chronic pathological remodeling of the kidney in which the normal tissue architecture is progressively replaced by type I collagen and other extracellular matrix proteins 2, 4, 5 . Accumulation of type I collagen leads to structural and functional alterations of the kidney parenchyma and eventual organ failure. Most chronic renal damage, irrespective of etiology, leads to renal fibrosis, a self-perpetuating process that is probably facilitated by the recruitment of activated fibroblasts (myofibroblasts) and the propagation of an inflammatory response 1, 3, 6 . Many previous studies have suggested a possible role for myofibroblasts in the production of scarforming type I collagen and the pathogenesis of renal fibrosis 1, [6] [7] [8] .
We generated mice in which the gene for red fluorescent protein (RFP) was expressed under the control of the αSMA (α smooth muscle actin) promoter (referred to here as αSMA-RFP transgenic mice) (Supplementary Fig. 1 ). In healthy kidneys of αSMA-RFP transgenic mice, αSMA + cells were restricted to occasional rare interstitial cells and smooth muscle cells, whereas we found a significant increase in the number of interstitial αSMA + cells (tenfold increase) after unilateral ureteral obstruction (UUO) (Fig. 1a) . We isolated αSMA + cells from control and fibrotic kidneys of αSMA-RFP transgenic mice using fluorescence-activated cell sorting, expanded them (Fig. 1b) and performed gene expression profiling to identify candidate genes that may mediate fibrosis. Pathway analysis revealed alterations in genes associated with transforming growth factor β (TGF-β)-mediated cytoskeleton remodeling, mesenchymal phenotype acquisition, cell adhesion and transport of clathrin-coated vesicles ( Supplementary  Fig. 2 ). Upregulated genes included those encoding for extracellular matrix proteins, including Bgn (encoding biglycan), Des (encoding desmin) and Dcn (encoding decorin), as well as serine proteases, such as Prss35 and Prss23, and protease inhibitors, including SerpinF1 and Serpina10 (Supplementary Table 1) . Notably, the most highly upregulated gene in this array analysis (with 37-fold increased regulation) was Wfdc2, which encodes for the mouse homolog of HE4 (we use 'HE4' hereafter to indicate both the mouse Wfdc2 and human WFDC2 gene products) (Supplementary Table 1 ). Although many of the other top upregulated genes have been previously reported to have a role in liver, lung, colon or kidney fibrosis (Supplementary Table 1) , our expression profiling data identified HE4 as a new gene with potential implications for fibrosis. Real-time PCR analysis revealed a 12-fold upregulation of HE4 in fibrosis-associated fibroblasts (FAFs) (Fig. 1c) . Western blot analyses detected HE4 in FAF lysates and culture media as a single band (Fig. 1d,e and Supplementary Fig. 3a,b) . We also found elevated HE4 expression in fibrotic kidneys (Fig. 1f,g and Supplementary Fig. 3a,b) .
The four-disulfide core domain repeats, or WAP functional motif, of HE4 suggested protease inhibitor activity 9, 10 . Serine protease activity in fibrotic kidney lysates was significantly inhibited when they were preincubated with recombinant HE4 protein (Fig. 2a) . In this assay, an increase in the degradation of the substrate BAPNA, measured using spectrophotometric detection of the released p-nitroaniline (pNA) product, indicates an increase in serine protease activity. Addition of HE4 to fibrotic kidney lysates reduced pNA concentrations, which is indicative of its capacity to function as an inhibitor of enzymes with Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis trypsin-like serine protease activity. The FAF and fibrotic kidney 11 gene expression profiles identified the upregulation of two serine proteases with unknown roles in renal fibrosis, Prss35 and Prss23. Validation by real-time PCR revealed 3-and 1.5-fold upregulation of Prss35 and 2.1-and 2.5-fold upregulation of Prss23 in FAFs and fibrotic kidneys, respectively (Fig. 2b) . Both Prss23 and Prss35 showed gelatinolytic activity in a zymogram assay (data not shown), and HE4 specifically inhibited Prss35 and Prss23 serine protease activity and their capacity to degrade type I collagen (Fig. 2c,d ). Hydroxyproline release assays measure collagen triple-helix degradation. We found an increase in released hydroxyproline when we subjected type I collagen to either Prss35 or Prss23 serine proteases (Fig. 2d) . HE4 inhibited Prss35-and Prss23-mediated degradation of type I collagen (Fig. 2d) . Further, the inhibitory activity of HE4 on Prss35 and Prss23 was suppressed by the addition of HE4-neutralizing antibodies (Fig. 2d) . We also directly evaluated HE4 inhibition of trypsin and found that HE4 inhibited the enzyme activity of purified trypsin and its activity in fibrotic kidney lysates ( Fig. 2e and Supplementary Fig. 3c ). HE4 also reduced trypsin degradation of type I collagen, and HE4-neutralizing antibodies reversed this action (Fig. 2f) .
We next evaluated whether the ability of recombinant human matrix metalloproteinase 2 (MMP2) and MMP9 to degrade type I collagen could be inhibited by HE4. A hydroxyproline release assay showed that HE4 significantly suppressed the activities of MMP2 and MMP9 to degrade type I collagen (Fig. 2g) . Further, we found that HE4 directly interacts with MMP2 and MMP9, as assessed by immunoprecipitation using antibody to HE4 and subsequent western blotting analysis (Fig. 2h) . HE4 also inhibited the degradation of type I collagen by bacterial collagenase, a collagenase that shares an activity profile with many mammalian MMPs (Supplementary Fig. 3d ).
To functionally address the role of HE4 specifically in renal fibrosis, we administered an HE4-neutralizing antibody to mice after UUO.
Mice treated with the antibody to HE4 showed improvement in renal fibrosis when compared to mice treated with a control IgG antibody, as shown by a significant decrease in Masson's trichrome staining (75% reduction) and type I collagen content (80% reduction) in the mice treated with the antibody to HE4 (Fig. 3a) . In the nephrotoxic serum-induced nephritis (NTN) mouse model, treating mice with the HE4-neutralizing antibody also resulted in a significant reduction in Masson's trichrome staining (50% reduction) and type I collagen content (60% reduction), which is suggestive of reduced renal fibrosis (Fig. 3a) . Blood urea nitrogen and urine albuminto-creatinine ratio measurements showed that the treatment with antibody to HE4 improved renal functions in NTN mice (Fig. 3b) . We found similar results in mice with 5/6 nephrectomy ( Supplementary Fig. 4 ). Double immunolabeling for HE4 and αSMA indicated that the majority of HE4 + cells are also αSMA + (~80%). Mice treated with the antibody to HE4 showed a significant decrease in the number of HE4 + αSMA + double-positive cells compared to mice treated with the control IgG antibody ( Fig. 3c and Supplementary Fig. 5a ). Kidney lysates from UUO mice treated with IgG showed an overall increase in type I collagen digestion activity when compared to kidney lysates from contralateral control kidneys (Fig. 3d) . Kidney lysates from UUO mice treated with the antibody to HE4 showed an overall decrease in type I collagen degradation activity, including a decrease in type I collagen digestion mediated by MMP2 and MMP9, as assessed by gelatin zymography (Fig. 3d) . Serine protease activity in fibrotic kidney lysates was significantly increased in comparison to nonfibrotic kidney lysates (Fig. 3e) . Treatment with HE4-neutralizing antibodies also reduced trypsin and trypsin-like serine protease activity in kidney lysates from treated mice when compared to kidney lysates from IgG-treated control mice (Fig. 3e) . These results reflect an overall decrease in protease activity as a measure of improved kidney histology resulting from a reduction in fibrosis in the mice treated with antibody to HE4 at the experimental endpoint (day 10 after UUO). We evaluated MMP expression by western blot analyses of normal and fibrotic mouse kidney lysates. MMP2 and MMP9 were significantly upregulated in the fibrotic kidney lysates (Fig. 3f) , and we detected no MMP1, MMP3, MMP8 or MMP12 in the fibrotic kidney lysates by western blotting or gelatin and casein zymography (data not shown) 12 . The amount of MMP9 protein was significantly reduced in kidney lysates from mice treated with the antibody to HE4 (Fig. 3f) , again reflecting an overall decrease in fibrosis and improvement in kidney histology in the treated mice rather than a direct effect of treatment with antibody to HE4 on MMPs at the experimental endpoint (day 10 after UUO). In this regard, macrophage infiltration was also reduced in mice treated with the antibody to HE4 as compared to the control mice treated with IgG ( Supplementary  Fig. 5b) . Migration, proliferation and αSMA expression of FAFs was not affected by the HE4-neutralizing antibody ( Supplementary  Fig. 5c-e) . Although the number of αSMA + cells decreased in kidneys from mice treated with the HE4-neutralizing antibody, the relative proportion of proliferating myofibroblasts, as measured by colocalization of αSMA and Ki67, remained similar. These results suggest that the HE4-neutralizing antibody treatment did not directly affect myofibroblast proliferation (Supplementary Fig. 5f ).
We also found upregulation of HE4, PRSS35 and PRSS23 in FAFs from human fibrotic kidneys (Fig. 4a,b) . Western blot analyses revealed an upregulation of HE4 in human FAFs (Fig. 4c) and showed that HE4 is secreted by human FAFs (Fig. 4d) . Immunolabeling studies further revealed renal interstitial and tubular expression of HE4 in human fibrotic kidneys (Fig. 4e) . Additionally, serum concentrations of HE4 were significantly elevated in patients with chronic renal disease with biopsyconfirmed fibrosis (~600 pM) when compared to control serum from healthy individuals (~180 pM) (Fig. 4f and Supplementary Table 2) .
HE4 encodes for a highly conserved WAP domain-containing protein, which is suggestive of putative serine protease inhibitor activity 9,10,13-15 . The protein is implicated in sperm maturation 9 and potentially has a role in natural immunity 16 , but the biological function of HE4 is unknown. Interestingly, HE4 was identified as the most upregulated gene in fibrotic kidneys of dogs 17 . HE4 was also reported to be significantly upregulated in fibrotic kidneys of mice 11, 18 , and its transcript level in human kidney transplant biopsies was found to be strongly correlated with low estimated glomerular filtration rate (eGFR) 19 . Despite these observations, the role of HE4 in renal fibrosis and its putative serine protease activity has remained unexplored. Members of the WFDC-domain protein family, with suspected antimicrobial and protease inhibitor activities (through their four-disulfide core domain repeats or WAP motifs), were initially described to be exclusively transcribed in the epididymis but were later identified to also be expressed in other regions of the male and female reproductive tract, kidney, respiratory tract and several tumor cell lines, including ovarian, colon, breast and renal cell lines 13, 20, 21 .
Here we show that HE4 is robustly expressed by myofibroblasts, and its concentration in the serum of patients with kidney diseases correlates with renal fibrosis and may therefore serve as a biomarker to predict fibrosis. A large-scale patient analysis is warranted to further validate these preliminary findings. In this regard, a serum HE4 (sHE4) detection test recently received clearance from the US Food and Drug Administration to aid in diagnosis and the monitoring of recurrence and progression in ovarian cancer, and a high concentration of sHE4 is a prognostic indicator and identifies high-risk patients with serous and endometrial cancer 22, 23 .
Our study identifies two new specific serine proteases (Prss23 and Prss35) as significantly upregulated in kidney fibrosis, which seem to act, at least in part, as type I collagen-degrading enzymes and targets of HE4 protease inhibition. In this regard, tissue inhibitors of npg l e t t e r S metalloproteases (TIMPs) and other inhibitors such as PAI-1 (also known as SerpinE1) have been studied for their role in the pathogenesis of organ fibrosis [24] [25] [26] . We also demonstrate that HE4 can inhibit degradation of type I collagen induced by MMP2 or MMP9, which can be reversed by the use of a neutralizing antibody to HE4. Although the activities of both MMP2 and MMP9 (and other proteins with type I collagen-degrading activities) were significantly reduced by HE4, the overall amount of MMP9 protein was also reduced in mice treated with antibody to HE4. Such a drop in MMP9 abundance could also reflect a secondary effect of the treatment with antibody to HE4 in resolving overall fibrosis and its associated inflammation. HE4 emerges as a potential pan-serine protease inhibitor, with a possible role for a substantial downregulation of serine protease activity in fibrotic kidneys. We speculate that such pan-protease inhibitory activity promotes a profibrotic process by inhibiting a number of enzymes that contribute to type I collagen turnover in the fibrotic kidney. Indeed, renal fibrosis in three different models can be inhibited by systemic administration of a HE4-neutralizing antibody. Collectively, our studies identify HE4 as a biomarker for detection of renal fibrosis and a target to inhibit renal fibrosis.
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